ڴŮ

Meeting Coverage

ASH Expert Roundtable: Multiple Myeloma

Expert Roundtable from the American Society of Hematology

Updated MajesTEC-1 Results Continue to Show Teclistamab's Promise

Vinay Prasad, MD, leads the roundtable discussion with Aaron Goodman, MD, and Manni Mohyuddin, MD

image

Latest ASH Expert Roundtable: Multiple Myeloma Meeting Coverage

Isatuximab Plus RVd Induction in Newly Diagnosed Multiple Myeloma

Vinay Prasad, MD, discusses the GMMG-HD7 trial with Aaron Goodman, MD, and Manni Mohyuddin, MD

January 4, 2022
Any Role for Maintenance Ixazomib in Multiple Myeloma?

Vinay Prasad, MD, leads a roundtable discussion with Aaron Goodman, MD, and Manni Mohyuddin, MD

December 27, 2021
The 'Messy' Data on Chromosome 1 Abnormalities and Multiple Myeloma Treatment

Vinay Prasad, MD, leads a roundtable discussion with Aaron Goodman, MD, and Manni Mohyuddin, MD

December 20, 2021
CAR-T for Myeloma Excites at ASH, but Questions Remain

Whether curative, accessibility concerns, and timing of treatment still need to be answered

January 22, 2021
FORTE Raises Question of Excessive Treatment in Myeloma

How much treatment is too much for newly diagnosed patients?

January 15, 2021
Many Questions Surround GRIFFIN Study

Vinay Prasad, MD, leads roundtable discussion with Aaron Goodman, MD, and Al-Ola Abdallah, MD

January 8, 2021
Selinexor OK'd for Myeloma, But Does That Make It a Good Drug?

Vinay Prasad, MD, leads the roundtable discussion with Aaron Goodman, MD, and Al-Ola Abdallah, MD

December 28, 2020
Early Transplant or Delayed? Multiple Myeloma Experts Debate

Vinay Prasad, MD, leads the roundtable discussion with Aaron Goodman, MD, and Al-Ola Abdallah, MD

December 18, 2020